Longidase, vaginal and rectal suppositories 3000 me 20 pcs

The prolongation of the enzyme action is achieved by covalent binding of the enzyme to the physiologically active polymeric carrier (azoximer). Longidase® shows antifibrotic properties, weakens acute phase of inflammation, regulates (increases or decreases depending on initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases humoral immune response and resistance of the body to infection.

The pronounced antifibrotic properties of Longidase are provided by conjugation of hyaluronidase with the carrier, which significantly increases resistance of the enzyme to denaturing influences and to the action of inhibitors: the enzymatic activity of Longidase is maintained when heated to 37 °С for 20 days, while the native hyaluronidase in the same conditions loses its activity within a day. </Longidase® simultaneously contains local presence of hyaluronidase enzyme and a carrier able to bind enzyme inhibitors and stimulators of collagen synthesis (iron ions, copper ions, heparin, etc.) released during hydrolysis of matrix components. Due to these properties Longidase® has not only the ability to depolymerize the matrix of connective tissue in fibrotic-granulematous formations, but also suppresses the reverse regulatory reaction directed to the synthesis of components of connective tissue.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.

Glycosaminoglycans change their basic properties as a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids): viscosity is reduced, the ability to bind water, metal ions is reduced, the permeability of tissue barriers is temporarily increased, fluid movement in the intercellular space is facilitated, the elasticity of connective tissue is increased, which is manifested in a reduction of tissue swelling, flattening of scars, increased joint movement, reduction of contractures and prevention of their formation, reduction of adhesions.

Biochemical, immunological, histological and electron-microscopic investigations prove that Longidase® does not damage the normal connective tissue, but causes destruction of the connective tissue altered in composition and structure in the area of fibrosis.

Longidaza® has no mutagenic, embryotoxic, teratogenic and carcinogenic effect.

The drug is well tolerated by patients, no local and general allergic reactions were noted.

The use of Longidase in therapeutic doses during or after surgical treatment does not cause deterioration of the course of postoperative period or progression of the infection; it does not slow down bone regeneration.

Indications

Adults and adolescents over 12 years of age as monotherapy and as part of complex therapy for diseases accompanied by connective tissue hyperplasia, including against the background of an inflammatory process:
in urology: chronic prostatitis, interstitial cystitis, strictures of the urethra and ureters, Peyronie’s disease, the initial stage of benign prostatic hyperplasia, prevention of scar formation and strictures after surgical interventions on the urethra, bladder, ureters;
in gynecology: adhesions (prevention and treatment) in the pelvis in chronic inflammatory diseases of the internal genital organs, after gynecological manipulations, including induced abortions, previous surgical interventions on the pelvic organs; intrauterine synechiae, tubo-peritoneal infertility, chronic endomyometritis;
in dermatovenerology: limited scleroderma, prevention of fibrous complications of sexually transmitted infections;
in surgery: prevention and treatment of adhesions after surgical interventions on the abdominal organs; long-term non-healing wounds;
in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous fibrous, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy;
to increase the bioavailability of antibacterial therapy in urology, gynecology, dermatovenerology, surgery, pulmonology, etc.

Pharmacological effect

Prolongation of the action of the enzyme is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azoximer). Longidase® exhibits antifibrotic properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor alpha), increases the humoral immune response and the body’s resistance to infection.

The pronounced antifibrotic properties of Longidase are ensured by the conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing influences and the action of inhibitors: the enzymatic activity of Longidase is maintained when heated to 37 ° C for 20 days, while native hyaluronidase loses its activity within 24 hours under the same conditions.

The Longidaza® preparation ensures the simultaneous local presence of the enzyme hyaluronidase and a carrier capable of binding enzyme inhibitors and stimulators of collagen synthesis (iron, copper ions, heparin, etc.) released during hydrolysis of matrix components. Thanks to these properties, Longidaza® not only has the ability to depolymerize the connective tissue matrix in fibrogranulomatous formations, but also suppress the reverse regulatory reaction aimed at the synthesis of connective tissue components.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.

As a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water and metal ions decreases, the permeability of tissue barriers temporarily increases, the movement of fluid in the intercellular space is facilitated, the elasticity of connective tissue increases, which is manifested in a decrease in tissue swelling, flattening of scars, increased range of motion of joints, reducing contractures and preventing their formation, reducing adhesions.

Biochemical, immunological, histological and electron microscopic studies have proven that Longidaza® does not damage normal connective tissue, but causes destruction of connective tissue altered in composition and structure in the area of ​​fibrosis.

Longidaza® does not have mutagenic, embryotoxic, teratogenic or carcinogenic effects.

The drug was well tolerated by patients, no local or general allergic reactions were noted.

The use of Longidase in therapeutic doses during or after surgical treatment does not cause worsening of the postoperative period or progression of the infectious process; does not slow down bone tissue recovery.

Special instructions

Stop using Longidase® if an allergic reaction develops.

When used against the background of exacerbation of foci of infection, to prevent the spread of infection, prescribe under the guise of antimicrobial agents.

Active ingredient

Bovhyaluronidase azoximer

Composition

Composition per suppository:

Active substance:

Bovhyaluronidase azoximer (Longidase®) – 3000 IU;

Excipient:

cocoa butter – until a suppository weighing 1.3 g is obtained

Contraindications

increased individual sensitivity to drugs with hyaluronidase activity, Longidase®;
malignant neoplasms;
pregnancy (no clinical experience of use);
children under 12 years of age (efficacy and safety have not been studied).

With caution (use no more than once a week): renal failure; history of pulmonary hemorrhage.

Side Effects

Rarely – allergic reactions with increased individual sensitivity.

Interaction

When using Longidase® in patients receiving large doses of salicylates, cortisone, ACTH, estrogens or antihistamines, the effectiveness of the hyaluronidase enzyme may be reduced.

When prescribed in combination with other drugs, the possibility of increasing their absorption (bioavailability) and enhancing systemic action should be taken into account.

Manufacturer

NPO Petrovax Pharm, Russia